Pharmamel Drug Disvoery Pharmamel Drug Disvoery Pharmamel Drug Disvoery Pharmamel Drug Disvoery
  • Home
  • Company
    • About us
    • Founding partners
    • Board of directors
    • Contact
  • Research
    • Pathologies
    • Clinical trials
    • Documents and publications
    • Collaborations
  • Patents
    • Melatonin injectable for Sepsis
    • Melatonin injectable for viral diseases
    • Melatonin injectable for Cancer
    • Licenses
  • Investors
    • Open capital round
    • Financial information
    • Other relevant information
    • Shareholder and investor information
    • Invest
  • News

  • English
  • Español

HomeNews

News

Pharmamel will go public to finance a revolutionary drug.

8 de May de 2024

Pharmamel announces the capital increase campaign “Go to BME Scaleup”

24 de April de 2024

Pharmamel launches the capital increase campaign “Go to BME Scaleup”

17 de April de 2024

The BME Pre-Market Environment welcomes Pharmamel

19 de March de 2024

Pharmamel begins the path to going public, entering the BME pre-market environment.

19 de March de 2024

Capital Cell invests in Pharmamel for the development of new drugs based on melatonin

24 de January de 2024

Pharmamel revolutionizes sepsis treatment with a melatonin drug

21 de June de 2023

PROJECT ID: IDI-20200938

PROJECT TITLE: DEVELOPMENT OF TRIALS FOR THE PREVENTION OF MORTALITY ASSOCIATED WITH SARS-COV2 (COVID-19) INFECTION IN HOSPITALIZED PATIENTS
Summary: This involves the development of a project through which to demonstrate the efficacy of injectable Melatonin for the prevention of mortality associated with SARS-Cov2 (COVID-19) infection in hospitalized patients.
Grant amount: €606,511.31

Contact
  • +34 958 419 143
  • C/ Ganivet 6, oficina 20-21. 18009 Granada
  • info@pharmameldrugdiscovery.com
Information
  • Privacy policy
  • Cokies policy

PHARMAMEL S.L. © 2024

Pharmamel Drug Disvoery
  • Home
  • Company
    • About us
    • Founding partners
    • Board of directors
    • Contact
  • Research
    • Pathologies
    • Clinical trials
    • Documents and publications
    • Collaborations
  • Patents
    • Melatonin injectable for Sepsis
    • Melatonin injectable for viral diseases
    • Melatonin injectable for Cancer
    • Licenses
  • Investors
    • Open capital round
    • Financial information
    • Other relevant information
    • Shareholder and investor information
    • Invest
  • News
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}